Send to

Choose Destination
Arch Gerontol Geriatr. 1992 Nov-Dec;15(3):225-37.

Evaluation of the clinical efficacy of idebenone in patients affected by chronic cerebrovascular disorders.

Author information

Division of Geriatrics and Rehabilitation, U.S.L. 04, Avellino, Italy.


This study evaluated the efficacy and tolerability of idebenone, a new neuroactive drug, in 33 patients aged from 50 to 80 years. They were affected by chronic cerebrovascular disease (CCVD) and their last cerebrovascular accident had taken place at least 3 months prior to enrollment. All these subjects presented a score within the range of the following psychometric scales: Hamilton Scale for Depression <24; Hachinski Dementia Score >/=18 and < 25; Mini Mental State >/=16 and </=22; Hachinski Ischemic Score </=7. Even without a cortical degenerative disease, their cerebral computerized tomography (CT) scan had to be positive for CCVD. The study was divided into three different periods: (1) 7 days from the enrollment and wash-out; (2) 3 months of treatment (idebenone 45 mg b.i.d. per os); (3) 1 week for the follow up. During the study, the following evaluation scales were administered: Sandoz Clinical Assessment of Geriatrics (SCAG), Gottfries-Brane-Steen (GBS), Instrumental Activity of Daily Living (IADL), Greene Relatives' Stress Scale (GRSS), Toulouse PiƩron, Randt Memory Test. The results show that idebenone is effective both in improving the sense of psycho-physical wellbeing and in improving cognitive, attentive and behavioural efficiency. The tolerability of the treatment was very good.

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center